Your web browser is out of date.

For your security and improved experience online, please update your browser.
Update your browser

Diabetes on the Net is intended for healthcare professionals

back to main site

Back

resources

Lilly

Go to website

on-demand video

An evidence-informed yet person-centred approach to the management of cardiovascular risk in type 2 diabetes

Learning objectives:

  • To discuss case studies of typical patients with type 2 diabetes, including assessment of their residual cardiovascular risk
  • To discuss the multiple strategies for reducing cardiovascular risk in people living with type 2 diabetes

This promotional video presentation was originally broadcast on 16 September 2021. Please note that the speakers are not able to answer questions from attendees watching the video on-demand.


Click here for Trulicity® (dulaglutide) Prescribing Information and Adverse Event Reporting

Adverse events and products complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and products complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.

Resources

A practical guide for Healthcare Professionals

For HCPs in Ireland and Northern Ireland only.
A GLP-1 Receptor Agonist designed with the patient in mind

For HCPs in Ireland and Northern Ireland only.
A practical guide for Healthcare Professionals

For HCPs in Great Britain only.
A GLP-1 Receptor Agonist designed with the patient in mind

For HCPs in Great Britain only.

Resources for online viewing only.

Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• in addition to other medicinal products for the treatment of diabetes mellitus

Company profile

Lilly has been a global leader in diabetes care since 1923. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions – from medicines to support programmes and more – we strive to make life better for all those affected by diabetes around the world.

This content is for UK & ROI Healthcare Professionals only. Lilly has provided sponsorship for the delivery of the conference and have only had input into the symposium sessions which they have sponsored.

 

This content is for UK & ROI Healthcare Professionals only. This resource page and the materials included have been organised and supported by Lilly.

PP-LD-IE-0061 | November 2021

get the latest news

subscribe now

© Copyright OmniaMed Communications. All Rights Reserved

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

Confirm
* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.